Skip to main content
SpringerLink
Log in

Pathology, Pathogenesis, Clinical Features, and Diagnosis

  • Chapter
  • First Online:
Gastrointestinal Cancer

  • 391 Accesses

Abstract

Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system, which can be classified as intrahepatic, perihilar, and distal. Each anatomic subtype has distinct genetic aberrations, clinical presentations, and therapeutic approaches. In this chapter, a comprehensive review of pathology, pathogenesis, clinical features, and diagnostic approach of CCA will be provided and discussed.

Dong-Won Ahn is the lead author of this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chan-On W, Nairismagi ML, Ong CK, Lim WK, Dima S, Pairojkul C, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013;45:1474–8.

    Article  CAS  PubMed  Google Scholar 

  2. Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7:1116–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003–10.

    Article  CAS  PubMed  Google Scholar 

  4. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;18:2780–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45:1470–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Liu ZH, Lian BF, Dong QZ, Sun H, Wei JW, Sheng YY, et al. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2360–8.

    Article  CAS  PubMed  Google Scholar 

  7. Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24:4154–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44:690–3.

    Article  CAS  PubMed  Google Scholar 

  9. Zou S, Li J, Zhou H, Frech C, Jiang X, Chu JS, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014;5:5696.

    Article  CAS  PubMed  Google Scholar 

  10. Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7(1):65.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, et al. Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell. 2017;32:57–70.e3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabro R, Pinyol R, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 2020;73:315–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087.

    Article  CAS  PubMed  Google Scholar 

  14. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3:636–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Suttiprapa S, Sotillo J, Smout M, Suyapoh W, Chaiyadet S, Tripathi T, et al. Opisthorchis viverrini proteome and host-parasite interactions. Adv Parasitol. 2018;102:45–72.

    Article  PubMed  Google Scholar 

  16. Siripongsakun S, Sapthanakorn W, Mekraksakit P, Vichitpunt S, Chonyuen S, Seetasarn J, et al. Premalignant lesions of cholangiocarcinoma: characteristics on ultrasonography and MRI. Abdom Radiol (NY). 2019;44:2133–46.

    Article  PubMed  Google Scholar 

  17. Wu MY, Yiang GT, Cheng PW, Chu PY, Li CJ. Molecular targets in hepatocarcinogenesis and implications for therapy. J Clin Med. 2018;7(8):213.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Sripa B, Mairiang E, Thinkhamrop B, Laha T, Kaewkes S, Sithithaworn P, et al. Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology. 2009;50:1273–81.

    Article  CAS  PubMed  Google Scholar 

  19. Forrer A, Sayasone S, Vounatsou P, Vonghachack Y, Bouakhasith D, Vogt S, et al. Spatial distribution of, and risk factors for, Opisthorchis viverrini infection in southern Lao PDR. PLoS Negl Trop Dis. 2012;6:e1481.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Lun ZR, Gasser RB, Lai DH, Li AX, Zhu XQ, Yu XB, et al. Clonorchiasis: a key foodborne zoonosis in China. Lancet Infect Dis. 2005;5:31–41.

    Article  PubMed  Google Scholar 

  21. Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res. 1978;38:4634–9.

    CAS  PubMed  Google Scholar 

  22. Pakharukova MY, Zaparina OG, Kovner AV, Mordvinov VA. Inhibition of Opisthorchis felineus glutathione-dependent prostaglandin synthase by resveratrol correlates with attenuation of cholangiocyte neoplasia in a hamster model of opisthorchiasis. Int J Parasitol. 2019;49:963–73.

    Article  CAS  PubMed  Google Scholar 

  23. Smout MJ, Sotillo J, Laha T, Papatpremsiri A, Rinaldi G, Pimenta RN, et al. Carcinogenic parasite secretes growth factor that accelerates wound healing and potentially promotes neoplasia. PLoS Pathog. 2015;11:e1005209.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Chaiyadet S, Sotillo J, Smout M, Cantacessi C, Jones MK, Johnson MS, et al. Carcinogenic liver fluke secretes extracellular vesicles that promote cholangiocytes to adopt a tumorigenic phenotype. J Infect Dis. 2015;212:1636–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Arunsan P, Ittiprasert W, Smout MJ, Cochran CJ, Mann VH, Chaiyadet S, et al. Programmed knockout mutation of liver fluke granulin attenuates virulence of infection-induced hepatobiliary morbidity. Elife. 2019;8:e41463.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Molecular mechanisms driving cholangiocarcinoma invasiveness: an overview. Gene Expr. 2018;18:31–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis of cholangiocarcinoma. BMC Cancer. 2019;19:185.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Roy S, Glaser S, Chakraborty S. Inflammation and progression of cholangiocarcinoma: role of angiogenic and lymphangiogenic mechanisms. Front Med (Lausanne). 2019;6:293.

    Article  PubMed  Google Scholar 

  29. Servais FA, Kirchmeyer M, Hamdorf M, Minoungou NWE, Rose-John S, Kreis S, et al. Modulation of the IL-6-signaling pathway in liver cells by miRNAs targeting gp130, JAK1, and/or STAT3. Mol Ther Nucleic Acids. 2019;16:419–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Alvaro D, Barbaro B, Franchitto A, Onori P, Glaser SS, Alpini G, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol. 2006;169:877–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005;24:5764–74.

    Article  CAS  PubMed  Google Scholar 

  32. Claperon A, Mergey M, Nguyen Ho-Bouldoires TH, Vignjevic D, Wendum D, Chretien Y, et al. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. J Hepatol. 2014;61:325–32.

    Article  CAS  PubMed  Google Scholar 

  33. Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 2011;105:131–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Pant K, Richard S, Peixoto E, Gradilone SA. Role of glucose metabolism reprogramming in the pathogenesis of cholangiocarcinoma. Front Med (Lausanne). 2020;7:113.

    Article  PubMed  Google Scholar 

  35. Phoomak C, Silsirivanit A, Wongkham C, Sripa B, Puapairoj A, Wongkham S. Overexpression of O-GlcNAc-transferase associates with aggressiveness of mass-forming cholangiocarcinoma. Asian Pac J Cancer Prev. 2012;13 Suppl:101–5.

    PubMed  Google Scholar 

  36. Phoomak C, Vaeteewoottacharn K, Sawanyawisuth K, Seubwai W, Wongkham C, Silsirivanit A, et al. Mechanistic insights of O-GlcNAcylation that promote progression of cholangiocarcinoma cells via nuclear translocation of NF-kappaB. Sci Rep. 2016;6:27853.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Phoomak C, Park D, Silsirivanit A, Sawanyawisuth K, Vaeteewoottacharn K, Detarya M, et al. O-GlcNAc-induced nuclear translocation of hnRNP-K is associated with progression and metastasis of cholangiocarcinoma. Mol Oncol. 2019;13:338–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Saengboonmee C, Seubwai W, Wongkham C, Wongkham S. Diabetes mellitus: possible risk and promoting factors of cholangiocarcinoma: association of diabetes mellitus and cholangiocarcinoma. Cancer Epidemiol. 2015;39:274–8.

    Article  PubMed  Google Scholar 

  39. Phoomak C, Vaeteewoottacharn K, Silsirivanit A, Saengboonmee C, Seubwai W, Sawanyawisuth K, et al. High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation. Sci Rep. 2017;7:43842.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Saengboonmee C, Seubwai W, Pairojkul C, Wongkham S. High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation. Sci Rep. 2016;6:18995.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Indramanee S, Sawanyawisuth K, Silsirivanit A, Dana P, Phoomak C, Kariya R, et al. Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway. Sci Rep. 2019;9:17266.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Phoomak C, Silsirivanit A, Park D, Sawanyawisuth K, Vaeteewoottacharn K, Wongkham C, et al. O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1. Oncogene. 2018;37:5648–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Park DD, Phoomak C, Xu G, Olney LP, Tran KA, Park SS, et al. Metastasis of cholangiocarcinoma is promoted by extended high-mannose glycans. Proc Natl Acad Sci U S A. 2020;117:7633–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Talabnin K, Talabnin C, Ishihara M, Azadi P. Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma. Oncol Lett. 2018;15:1030–6.

    PubMed  Google Scholar 

  45. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010;2:419–27.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261–80.

    Article  PubMed  Google Scholar 

  47. Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6:22–34.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Sirica AE, Dumur CI, Campbell DJ, Almenara JA, Ogunwobi OO, Dewitt JL. Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin Gastroenterol Hepatol. 2009;7:S68–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Bragazzi MC, Ridola L, Safarikia S, Matteo SD, Costantini D, Nevi L, et al. New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin. Ann Gastroenterol. 2018;31:42–55.

    PubMed  Google Scholar 

  50. Akita M, Sofue K, Fujikura K, Otani K, Itoh T, Ajiki T, et al. Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma. HPB (Oxford). 2019;21:226–34.

    Article  PubMed  Google Scholar 

  51. Bae JY, Park YN, Nakanuma Y, Lee WJ, Kim JY, Park C. Intestinal type cholangiocarcinoma of intrahepatic large bile duct associated with hepatolithiasis—a new histologic subtype for further investigation. Hepatogastroenterology. 2002;49:628–30.

    PubMed  Google Scholar 

  52. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology. 2018;68:113–26.

    Article  PubMed  Google Scholar 

  53. Balitzer D, Joseph NM, Ferrell L, Shafizadeh N, Jain D, Zhang X, et al. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma. Mod Pathol. 2019;32:1486–94.

    Article  CAS  PubMed  Google Scholar 

  54. Brivio S, Cadamuro M, Strazzabosco M, Fabris L. Tumor reactive stroma in cholangiocarcinoma: the fuel behind cancer aggressiveness. World J Hepatol. 2017;9:455–68.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Bosmuller H, Pfefferle V, Bittar Z, Scheble V, Horger M, Sipos B, et al. Microvessel density and angiogenesis in primary hepatic malignancies: differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Pathol Res Pract. 2018;214:1136–41.

    Article  PubMed  Google Scholar 

  56. Xu J, Igarashi S, Sasaki M, Matsubara T, Yoneda N, Kozaka K, et al. Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers. Liver Int. 2012;32:1156–64.

    Article  PubMed  Google Scholar 

  57. Cadamuro M, Stecca T, Brivio S, Mariotti V, Fiorotto R, Spirli C, et al. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1435–43.

    Article  CAS  PubMed  Google Scholar 

  58. Loeuillard E, Conboy CB, Gores GJ, Rizvi S. Immunobiology of cholangiocarcinoma. JHEP Rep. 2019;1:297–311.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Vaquero J, Aoudjehane L, Fouassier L. Cancer-associated fibroblasts in cholangiocarcinoma. Curr Opin Gastroenterol. 2020;36:63–9.

    Article  CAS  PubMed  Google Scholar 

  60. Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell. 2021;39:866–882.e11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Alvaro D, Bragazzi MC, Benedetti A, Fabris L, Fava G, Invernizzi P, et al. Cholangiocarcinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “Cholangiocarcinoma” Committee of the Italian Association for the study of liver disease. Dig Liver Dis. 2011;43:60–5.

    Article  PubMed  Google Scholar 

  63. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:204–7.

    Article  CAS  PubMed  Google Scholar 

  64. Kim MJ, Choi JY, Chung YE. Evaluation of biliary malignancies using multidetector-row computed tomography. J Comput Assist Tomogr. 2010;34:496–505.

    Article  PubMed  Google Scholar 

  65. Wildner D, Bernatik T, Greis C, Seitz K, Neurath MF, Strobel D. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients—early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med. 2015;36:132–9.

    Article  CAS  PubMed  Google Scholar 

  66. Iavarone M, Piscaglia F, Vavassori S, Galassi M, Sangiovanni A, Venerandi L, et al. Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. J Hepatol. 2013;58:1188–93.

    Article  PubMed  Google Scholar 

  67. Kim SH, Lee CH, Kim BH, Kim WB, Yeom SK, Kim KA, et al. Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2012;36:704–9.

    Article  PubMed  Google Scholar 

  68. Choi SH, Lee SS, Kim SY, Park SH, Park SH, Kim KM, et al. Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology. 2017;282:771–81.

    Article  PubMed  Google Scholar 

  69. Vilana R, Forner A, Bianchi L, Garcia-Criado A, Rimola J, de Lope CR, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology. 2010;51:2020–9.

    Article  PubMed  Google Scholar 

  70. Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol. 2006;45:43–50.

    Article  PubMed  Google Scholar 

  71. Lamarca A, Barriuso J, Chander A, McNamara MG, Hubner RA, ÓReilly D, et al. (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis. J Hepatol. 2019;71:115–29.

    Article  PubMed  Google Scholar 

  72. Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging. 2015;42:1165–79.

    Article  PubMed  Google Scholar 

  73. Saluja SS, Sharma R, Pal S, Sahni P, Chattopadhyay TK. Differentiation between benign and malignant hilar obstructions using laboratory and radiological investigations: a prospective study. HPB (Oxford). 2007;9:373–82.

    Article  PubMed  Google Scholar 

  74. Trikudanathan G, Navaneethan U, Njei B, Vargo JJ, Parsi MA. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79:783–9.

    Article  PubMed  Google Scholar 

  75. Barr Fritcher EG, Voss JS, Brankley SM, Campion MB, Jenkins SM, Keeney ME, et al. An optimized set of fluorescence in situ hybridization probes for detection of pancreatobiliary tract cancer in cytology brush samples. Gastroenterology. 2015;149:1813–1824.e1.

    Article  CAS  PubMed  Google Scholar 

  76. Rizvi S, Eaton J, Yang JD, Chandrasekhara V, Gores GJ. Emerging technologies for the diagnosis of perihilar cholangiocarcinoma. Semin Liver Dis. 2018;38:160–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Mohamadnejad M, DeWitt JM, Sherman S, LeBlanc JK, Pitt HA, House MG, et al. Role of EUS for preoperative evaluation of cholangiocarcinoma: a large single-center experience. Gastrointest Endosc. 2011;73:71–8.

    Article  PubMed  Google Scholar 

  78. Heimbach JK, Sanchez W, Rosen CB, Gores GJ. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford). 2011;13:356–60.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea (Republic of)

    Hoon Jai Chun

  2. Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea (Republic of)

    Seun Ja Park

  3. Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Kyonggi-do, Korea (Republic of)

    Yun Jeong Lim

  4. Department of Internal Medicine, Yonsei University Severance Hospital, Seoul, Korea (Republic of)

    Si Young Song

Authors
  1. Hoon Jai Chun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seun Ja Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yun Jeong Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Si Young Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chun, H.J., Park, S.J., Lim, Y.J., Song, S.Y. (2023). Pathology, Pathogenesis, Clinical Features, and Diagnosis. In: Gastrointestinal Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-99-0815-8_53

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-0815-8_53

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-0814-1

  • Online ISBN: 978-981-99-0815-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation